Intervention
Genetic senescent-cell clearance (INK-ATTAC / p16 ablation)
Mechanism, regulatory status, and an honest, tiered evidence map.
○ Human lifespan evidence: none (animal/preclinical or mechanism only)
What it is
Class: Research tool (transgenic), NOT a therapy
Also known as: INK-ATTAC, p16-3MR, genetic senolysis
Relationship to senescence: Engineered mouse systems that induce apoptosis specifically in p16INK4a-expressing cells on demand. They provide the causal proof that senescent-cell burden drives aging phenotypes — but they are laboratory tools, not drugs, and cannot be given to humans.
Regulatory status
Not a therapeutic; a transgenic research model. No human application.
Mechanism
Drug-inducible dimerizer triggers apoptosis in p16-high cells, allowing clean tests of what removing senescent cells does. See /p16-ink4a and /senescent-cell-burden-aging.
Evidence — Mouse (transgenic)
| Species / population | INK-ATTAC transgenic mice (progeroid and wild-type backgrounds). |
| Exposure, route, schedule | Inducer (AP20187) administered to trigger p16-cell apoptosis. |
| Comparator / duration | Vehicle-treated transgenic littermates. |
| Endpoint / numeric result | Delayed multiple age-related disorders (2011); extended median lifespan in wild-type mice (2016). |
| What it did NOT establish | A genetic tool result does not transfer to any human drug; it motivates, but does not validate, pharmacological senolytics. |
Negative or null findings
- Genetic clearance is not achievable pharmacologically today; benefits seen in these models have not been reproduced by any drug in humans.